PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas

• Published in: Frontiers in immunology 2021-02, Vol.12, p.628966-628966
• Main Authors: Zhang, Hao, He, Jialin, Dai, Ziyu, Wang, Zeyu, Liang, Xisong, He, Fengqiong, Xia, Zhiwei, Feng, Songshan, Cao, Hui, Zhang, Liyang, Cheng, Quan
• Format: Article
• Language: English
• Subjects: gliomas; immune infiltration; Immunology; immunotherapy; PDIA5; scRNA-seq
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.628966

Gliomas are the most common and lethal primary malignant tumor of the brain. Routine treatment including surgical resection, chemotherapy, and radiotherapy produced limited therapeutic effect, while immunotherapy targeting the glioma microenvironment has offered a novel therapeutic option. PDIA5 protein is the member of PDI family, which is highly expressed in glioma and participates in glioma progression. Based on large-scale bioinformatics analysis, we discovered that PDIA5 expression level is upregulated in aggressive gliomas, with high PDIA5 expression predicting poor clinical outcomes. We also observed positive correlation between PDIA5 and immune infiltrating cells, immune related pathways, inflammatory activities, and other immune checkpoint members. Patients with high PDIA5 high-expression benefited from immunotherapies. Additionally, immunohistochemistry revealed that PDIA5 and macrophage biomarker CD68 were upregulated in high-grade gliomas, and patients with low PDIA5 level experienced favorable outcomes among 33 glioma patients. Single cell RNA sequencing exhibited that PDIA5 was in high level presenting in neoplastic cells and macrophages. Cell transfection and co-culture of glioma cells and macrophages revealed that PDIA5 in tumor cells mediated macrophages exhausting. Altogether, our findings indicate that PDIA5 overexpression is associated with immune infiltration in gliomas, and may be a promising therapeutic target for glioma immunotherapy.